비교리스트

 카트 문의
시장보고서
상품코드
1606442

세계의 대상포진 백신 시장 : 제품 유형별, 백신 유형별, 용도별, 국가별, 지역별 - 산업 분석, 시장 용도, 시장 점유율, 예측(2024-2032년)

Shingles Vaccine Market, By Product Type, By Vaccine Type, By Application, By Country, and By Region - Industry Analysis, Market Application, Market Share & Forecast from 2024-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 269 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

2023년 대상포진 백신 시장 규모는 42억 5,493만 달러로 평가되었고, 2024년부터 2032년까지 연평균 15.50%의 성장률을 나타낼 것으로 예상됩니다.

대상포진 백신 시장 - 시장 역학

대상포진에 대한 인식이 높아지고 면역 결핍 질환의 발생률이 증가함에 따라 시장 수요를 촉진할 것으로 예상됩니다.

당뇨병, 암, HIV/AIDS, 면역억제제 사용 증가는 대상포진에 대한 감수성을 증가시키고 위험군에 대한 백신 접종의 필요성을 증가시켜 시장 성장을 가속할 것으로 보입니다. 보건 의료 기관의 인식 개선 캠페인은 대상포진의 위험과 대상포진 후 신경통(PHN)과 같은 심각한 합병증을 강조하여 백신 접종을 장려하고 있으며, CDC와 각국 보건부는 노인 대상포진 백신 접종을 촉진하기 위한 교육 이니셔티브를 시행하고 있습니다. 60세 이상 인구는 2050년까지 두 배로 증가할 것으로 예상되어 대상 인구가 크게 확대될 것으로 예상됩니다.

백신 기술의 발전도 시장 성장을 가속할 것으로 예상됩니다. 유전자 재조합 대상포진 백신인 신그리릭스(Syngrix)의 개발 등 기술 혁신으로 백신의 효능과 안전성이 향상되어 조스타박스와 같은 기존 약독화 생백신을 능가하는 백신 채택이 증가하고 있습니다. 최근 코로나19 팬데믹으로 인해 감염병 예방에 있어 백신의 중요성이 부각되면서 대상포진을 포함한 다른 중요한 백신에 대한 관심이 높아지고 있습니다.

대상포진 백신 시장 - 주요 인사이트

당사의 리서치 애널리스트의 분석에 따르면, 세계 시장은 예측 기간(2024-2032년) 동안 매년 약 15.50%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

제품 유형별로는 부작용에 대한 효과로 인해 2023년 시장싱글릭스(Syngrix)가 가장 큰 시장 점유율을 차지할 것으로 예측됩니다.

백신 유형별로 보면, 2023년 재조합 백신 부문은 바이러스 균주에 광범위하게 적용되어 백신 유형 부문을 주도했습니다.

용도별로는 백신 접종 프로그램 채택이 증가함에 따라 약물 전달 분야가 2023년 주요 응용 분야가 될 것으로 예상됩니다.

지역별로는 북미가 2023년 주요 수익원이 될 것으로 예상되며, 시장 상위 기업의 존재로 인해 북미가 주요 수익원이 될 것으로 보입니다.

대상포진 백신 시장 - 세분화 분석 :

세계 대상포진 백신 시장은 제품 유형, 백신 유형, 용도 및 지역에 따라 세분화됩니다.

시장은 제품 유형에 따라 신글릭스, 조스타박스, 스카이조스터의 세 가지 범주로 나뉩니다. 시장을 독점하고 있는 것은 신글릭스 부문입니다. 비용 효율성이 높기 때문에 SKYZoster 시장이 가장 빠르게 성장할 것으로 추정됩니다.

백신의 유형에 따라 시장은 재조합 백신과 약독성 생백신 두 가지로 나뉩니다. 재조합 백신 분야가 시장을 독점하고 있습니다. 재조합 DNA 기술의 채택으로 이러한 백신에 대한 수요가 증가하고 있습니다.

이 시장은 용도에 따라 연구, 약물 전달 및 기타 세 가지 범주로 나뉩니다. 약물 전달 분야가 세계 시장을 주도하고 있습니다. 백신의 장기 면역능력과 약물 전달의 효율성이 이 분야의 성장을 가속할 것으로 예상됩니다.

대상포진 백신 시장 - 지리적 통찰력

지역적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에 걸쳐 분포되어 있습니다. 북미는 대상포진 백신 시장을 독점하고 있으며, 강력한 의료 인프라, 높은 인지도, 신글릭스와 같은 백신이 크게 보급된 것이 그 요인으로 작용하고 있습니다. 유럽은 2위 시장으로 영국, 독일, 프랑스 등의 국가에서 백신 보급이 활발히 이루어지고 있으며, ECDC(European Centre for Disease Prevention and Control)의 백신 접종 정책 조정을 위한 노력이 시장 성장을 견인할 것으로 예상됩니다. 시장 성장을 견인할 것으로 예상됩니다. 아시아태평양은 의료 접근성 향상, 가처분 소득 증가, 고령 인구 증가로 인해 빠른 성장세를 보이고 있습니다.

대상포진 백신 시장 - 경쟁 구도:

대상포진 백신 시장은 인식 개선, 대상포진 발병률 증가, 정부의 백신 접종 프로그램에 힘입어 경쟁이 치열하게 전개되고 있습니다. GSK와 머크(Merck & Co., Ltd.)의 대상포진 백신은 높은 효능과 고령층에 대한 사용 권장 증가로 인해 세계 시장에서 큰 시장 점유율을 차지하고 있습니다. 각 업체들은 mRNA 기반 백신에 투자하고 있으며, SK케미칼과 녹십자 등 혁신적인 백신을 도입한 기업들도 있습니다.

2024년 4월, GSK는 ZOSTER-049 시험 결과를 발표하여 싱그릭스가 50세 이상 노인을 효과적으로 보호한다고 밝혔습니다.

2023년 2월 화이자(Pfizer)와 바이오엔텍(BioNTech)은 mRNA 기반 대상포진 백신의 임상시험을 시작했습니다.

목차

제1장 대상포진 백신 시장 개요

  • 조사 범위
  • 시장 추정년도

제2장 주요 요약

  • 시장 내역
  • 경쟁 인사이트

제3장 대상포진 백신 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장 향후 동향

제4장 대상포진 백신 산업 연구

  • PEST 분석
  • Porter의 Five Forces 분석
  • 성장 전망 매핑
  • 규제 구조 분석

제5장 대상포진 백신 시장 : COVID-19의 영향 분석

  • COVID-19 이전의 영향 분석
  • COVID-19 이후의 영향 분석

제6장 대상포진 백신 시장 구도

  • 대상포진 백신 시장 점유율 분석, 2023년
  • 주요 제조업체별 분석 데이터
    • 기존 기업 분석
    • 신규 기업 분석

제7장 대상포진 백신 시장 : 제품 유형별

  • 개요
    • 제품 유형별 부문 점유율 분석
    • Shingrix
    • Zostavax
    • SKYZoster

제8장 대상포진 백신 시장 : 백신 유형별

  • 개요
    • 백신 유형별 부문 점유율 분석
    • 재조합 백신
    • 생약독화 백신

제9장 대상포진 백신 시장 : 용도별

  • 개요
    • 용도별 부문 점유율 분석
    • 연구
    • 약물전달
    • 기타

제10장 대상포진 백신 시장 : 지역별

  • 서론
  • 북미
    • 개요
    • 북미 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제11장 주요 벤더 분석 - 대상포진 백신 업계

  • 경쟁 대시보드
  • 기업 개요
    • GlaxoSmithKline(GSK)
    • Merck &Co., Inc.
    • Pfizer Inc.
    • SK Chemicals
    • Green Cross Corp
    • Geneone Life Science
    • Vaccitech
    • CanSinoBIO
    • Jiangsu Recbio Technology Co., Ltd.
    • MedImmune LLC
    • AbbVie Inc.
    • Sanofi Pasteur
    • VBI Vaccines Inc.
    • Novavax Inc.
    • Bavarian Nordic
    • Others

제12장 애널리스트의 전방위 전망

LSH 24.12.19

REPORT HIGHLIGHT

Shingles Vaccine Market Application was valued at USD 4,259.43 Million in 2023, expanding at a CAGR of 15.50% from 2024 to 2032.

The shingles vaccine is a medical intervention designed to reduce the risk of developing shingles (herpes zoster), a painful rash caused by the reactivation of the varicella-zoster virus, the same virus responsible for chickenpox. Shingles predominantly affects older adults or individuals with weakened immune systems. The vaccine not only decreases the likelihood of shingles but also reduces the severity and duration of symptoms.

Shingles Vaccine Market- Market Dynamics

Increasing awareness about shingles and rising incidence of immunocompromising disorders is expected to propel market demand

Increasing prevalence of diabetes, cancer, HIV/AIDS, and the use of immunosuppressive drugs increase susceptibility to shingles, boosting the need for vaccination among at-risk groups, thereby fueling market growth. Awareness campaigns by healthcare organizations emphasize the risks of shingles and its severe complications, such as postherpetic neuralgia (PHN), encouraging vaccine uptake. The CDC and national health departments run educational initiatives promoting shingles vaccination among older adults. According to WHO, the global population aged 60 and above is expected to double by 2050, significantly expanding the target demographic.

Advancement in vaccine technology is also projected to enhance market growth. Innovations such as the development of Shingrix (a recombinant zoster vaccine) have improved vaccine efficacy and safety, encouraging adoption over older live-attenuated vaccines like Zostavax. Recently, the COVID-19 pandemic highlighted the importance of vaccines in preventing infectious diseases, spurring interest in other critical vaccines, including shingles.

Shingles Vaccine Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.50% over the forecast period (2024-2032)

Based on Product Type segmentation, the Shingrix segment was predicted to show maximum market share in the year 2023, owing to effectiveness in adverse events.

Based on Vaccine Type segmentation, the recombinant vaccine segment was the leading Vaccine Type segment in 2023, due to wider applications in virus strains.

Based on Application segmentation, the drug delivery segment was the leading Application segment in 2023, mainly due to the rising adoption of vaccination programs.

On the basis of region, North America was the leading revenue generator in 2023, due to the presence of top market players.

Shingles Vaccine Market- Segmentation Analysis:

Global Shingles Vaccine Market is segmented on the basis of Product Type, Vaccine Type, Application, and Region.

The market is divided into three categories based on the Product Type: Shingrix, Zostavax, and SKYZoster. The Shingrix segment dominates the market. The SKYZoster segment is estimated to grow at the fastest rate due to its high cost-effectiveness.

The market is divided into two categories based on Vaccine Type: recombinant vaccine and live attenuated vaccine. The recombinant vaccine segment dominates the market. With the adoption of recombinant DNA technology these vaccines are growing in demand.

The market is divided into three categories based on Application: research, drug delivery, and others. The drug delivery segment dominates the global market. The vaccines' ability to provide long-lasting immunity & efficiency in drug delivery is expected to boost segment growth.

Shingles Vaccine Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America dominates the shingles vaccine market, driven by strong healthcare infrastructure, high awareness, and significant uptake of vaccines like Shingrix. Europe is the second-largest market, with robust adoption in countries like the UK, Germany, and France. Increased efforts by the European Centre for Disease Prevention and Control (ECDC) to harmonize vaccination policies are expected to boost market growth. Asia-Pacific is experiencing rapid growth due to improved healthcare access, rising disposable incomes, and a growing elderly population.

Shingles Vaccine Market- Competitive Landscape:

The shingles vaccine market is highly competitive, driven by increasing awareness, rising incidence of shingles, and government-backed vaccination programs. The global market is dominated by a few key players, with GlaxoSmithKline (GSK) and Merck & Co. leading the field. GSK's Shingrix vaccine has a significant market share, largely due to its high efficacy and the growing recommendation for its use among older adults. Companies are investing in mRNA-based vaccines with some other significant players include SK Chemicals and Green Cross Corp, which are introducing innovative vaccines.

In April 2024, GSK showed results from the ZOSTER-049 trial, which disclosed that Shingrix effectively protected people aged above 50.

In February 2023, Pfizer & BioNTech started trials for mRNA-based shingle vaccines.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SHINGLES VACCINE MARKET KEY PLAYERS

  • GlaxoSmithKline (GSK)
  • Merck & Co., Inc.
  • Pfizer Inc.
  • SK Chemicals
  • Green Cross Corp
  • Geneone Life Science
  • Vaccitech
  • CanSinoBIO
  • Jiangsu Recbio Technology Co., Ltd.
  • MedImmune LLC
  • AbbVie Inc.
  • Sanofi Pasteur
  • VBI Vaccines Inc.
  • Novavax Inc.
  • Bavarian Nordic
  • Others

GLOBAL SHINGLES VACCINE MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019-2032

  • Shingrix
  • Zostavax
  • SKYZoster

GLOBAL SHINGLES VACCINE MARKET, BY VACCINE TYPE- MARKET ANALYSIS, 2019-2032

  • Recombinant vaccine
  • Live attenuated vaccine

GLOBAL SHINGLES VACCINE MARKET, BY APPLICATION- MARKET ANALYSIS, 2019-2032

  • Research
  • Drug delivery
  • Others

GLOBAL SHINGLES VACCINE MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Shingles Vaccine Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Shingles Vaccine Market Snippet by Product Type
    • 2.1.2. Shingles Vaccine Market Snippet by Vaccine Type
    • 2.1.3. Shingles Vaccine Market Snippet by Application
    • 2.1.4. Shingles Vaccine Market Snippet by Country
    • 2.1.5. Shingles Vaccine Market Snippet by Region
  • 2.2. Competitive Insights

3. Shingles Vaccine Key Market Trends

  • 3.1. Shingles Vaccine Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Shingles Vaccine Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Shingles Vaccine Market Opportunities
  • 3.4. Shingles Vaccine Market Future Trends

4. Shingles Vaccine Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Shingles Vaccine Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Shingles Vaccine Market Landscape

  • 6.1. Shingles Vaccine Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Shingles Vaccine Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Shingrix
    • 7.1.3. Zostavax
    • 7.1.4. SKYZoster

8. Shingles Vaccine Market - By Vaccine Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Vaccine Type, 2024 & 2032 (%)
    • 8.1.2. Recombinant vaccine
    • 8.1.3. Live attenuated vaccine

9. Shingles Vaccine Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 9.1.2. Research
    • 9.1.3. Drug delivery
    • 9.1.4. Others

10. Shingles Vaccine Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Shingles Vaccine Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Shingles Vaccine Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Shingles Vaccine Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Shingles Vaccine Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Shingles Vaccine Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Shingles Vaccine Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. GlaxoSmithKline (GSK)
    • 11.2.2. Merck & Co., Inc.
    • 11.2.3. Pfizer Inc.
    • 11.2.4. SK Chemicals
    • 11.2.5. Green Cross Corp
    • 11.2.6. Geneone Life Science
    • 11.2.7. Vaccitech
    • 11.2.8. CanSinoBIO
    • 11.2.9. Jiangsu Recbio Technology Co., Ltd.
    • 11.2.10. MedImmune LLC
    • 11.2.11. AbbVie Inc.
    • 11.2.12. Sanofi Pasteur
    • 11.2.13. VBI Vaccines Inc.
    • 11.2.14. Novavax Inc.
    • 11.2.15. Bavarian Nordic
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제